February 27, 2024 10:09 AM ESTUpdated 03:40 PM
News Briefing

De­nali’s $500M place­ment; Brain health start­up rais­es $26M

ENDPOINTS

Plus, news about Healis Ther­a­peu­tics, NRx Phar­ma­ceu­ti­cals, and Nu­va­lent:

De­nali Ther­a­peu­tics’ $500M PIPE: The com­pa­ny is sell­ing near­ly 30 mil­lion shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times